Quick Details
|
Product Name |
DEGARELIX |
|
CAS |
214766-78-6 |
|
EINECS |
1312995-182-4 |
|
Molecular Formula |
C82H103ClN18O16 |
|
Molecular Weight |
1632.28 |
|
Appearance |
White powder |
|
Application |
Fadvanced prostate cancer treatment |
|
Purity |
99% |
Description
Digaric, a gonadotropin hormone-releasing hormone receptblocker, has been approved in the United States Europe fadvanced (hormone-dependent) prostate cancer treatment, in Japan fprostate cancer treatment.
A New Zealstudy found that digaricol was no less effective in suppressing testosterone at a castration level (i.e., less than 0.5 ng/mL) than liangpraline (7.5mg per month intramuscular injection) in prostate cancer patients who had been treated with endocrine therapy (excluding hormone neoadjuvant therapy). The paper was published online in the journal Drugs in April 2014.
In this study, compared with liangpraline, digaricol had a rapid inhibition of testosterone a rapid increase of various prostate-specific antigen (PSA) levels. Also, no testosterone surge slight increase occurred in patients treated with digaric.
Testosterone inhibition PSA levels were maintained during the 12-month study period could last fup to five years (extended study duration of the main trial) (this extended study included patients who had switched from leprodrine to digaricol).
In general, digaric is well tolerated most adverse events are mild to moderate. The most common adverse events are injection site reactions some events that reflect the expected effect of testosterone inhibition (e.g., hot flashes weight gain).
Therefore, digaric is an effective choice fthe treatment of prostate cancer patients with endocrine therapy.
